UK-based Indivior has filed patent lawsuits against Dr. Reddy's, Actavis, Par, Alvogen and Teva for infringement of United States Patent No. 9,931,305 (305) regarding their respective proposed generic versions of the company's Suboxone (buprenorphine and naloxone) sublingual film product, it was reported on Friday.
These lawsuits allege that the specified companies infringe the '305 patent that was issued on April 3 and which has been submitted for listing in the United States Food and Drug Administration's (FDA's) Orange Book.
The '305 patent claims film compositions having a substantially uniform distribution of active drug. Indivior has been involved in patent infringement litigation involving other, earlier issued patents covering SUBOXONE® Film with these same companies relating to their proposed generic products.
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment